LongBio Pharma (Suzhou) Co., Ltd. Stock Price

SEHK:1779 Community·HK$10.6b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create Narrative

1779 Share Price Performance

HK$142.80

11.00 (8.35%)

HK$142.80

11.00 (8.35%)

HK$142.80

Fri, 19 Jun 26

Share Pricen/a

1779 Community Narratives

There are no narratives available yet.

Create Narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Excellent balance sheet with very low risk.

2 Risks

0 Rewards

View Full Analysis

LongBio Pharma (Suzhou) Co., Ltd. Key Details

Last Reported Earnings

Dec 31, 2025

Next Reporting Earnings

n/a

: -2.37
: 0%
: 0%
: 24.9%

View Full Analysis

About 1779

Founded: 2020
Employees: 85
CEO: Heng Liu
WebsiteView website: www.longbio.com

LongBio Pharma (Suzhou) Co., Ltd. engages in discovery and development of biopharmaceuticals that targets allergic and autoimmune diseases in the People's Republic of China and Hong Kong. The company's products includes LP-003, an anti-IgE antibody with novel sequencing; LP-005, bi-functional antibody fusion protein; LP-00A, a bi-functional antibody for allergic diseases; LP-00C, a bi-functional antibody or fusion protein for B-cell mediated autoimmune diseases; and LP-00D, a bi-functional antibody or fusion protein complement inhibitor for specific tissues,organs and indications. The company was founded in 2020 and is based in Changshu, China.